Cargando…

Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review

BACKGROUND: Major depressive disorder (MDD) is associated with decreased patient well-being and symptoms that can cause substantial impairments in patient functioning and even lead to suicide. Worldwide, MDD currently causes the second-most years lived with disability and is predicted to become the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brockbank, James, Krause, Taryn, Moss, Emily, Pedersen, Anne Milthers, Mørup, Michael Frank, Ahdesmäki, Outi, Vaughan, Jake, Brodtkorb, Thor-Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977292/ https://www.ncbi.nlm.nih.gov/pubmed/33736649 http://dx.doi.org/10.1186/s12955-021-01723-x

Ejemplares similares

Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients
por: Bartha, Erzsebet, et al.
Publicado: (2013)

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
por: Rothwell, Ben, et al.
Publicado: (2020)

Pharmacological Treatment of Major Depressive Disorder in Adolescents
por: Farley, Rachel L.
Publicado: (2005)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews
por: Gartlehner, Gerald, et al.
Publicado: (2017)

Global HR competencies: mastering competitive value from the outside-in
por: Ulrich, Dave, et al.
Publicado: (2012)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?
por: Zhu, Yuncheng, et al.
Publicado: (2023)

Placebo Response of Non-Pharmacological and Pharmacological Trials in Major Depression: A Systematic Review and Meta-Analysis
por: Brunoni, André Russowsky, et al.
Publicado: (2009)

Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments
por: Maffioletti, Elisabetta, et al.
Publicado: (2020)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir, Süleyman, et al.
Publicado: (2015)

Magnetoencephalographic Correlates of Emotional Processing in Major Depression Before and After Pharmacological Treatment
por: Domschke, Katharina, et al.
Publicado: (2015)

Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review
por: Shim, In Hee, et al.
Publicado: (2018)

Network Pharmacology-Based and Experimental Identification of the Effects of Paeoniflorin on Major Depressive Disorder
por: Zhang, Sha, et al.
Publicado: (2022)

Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
por: Caldiroli, Alice, et al.
Publicado: (2021)

Mechanism of saikogenin G against major depressive disorder determined by network pharmacology
por: Hu, Lili, et al.
Publicado: (2022)

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
por: Chauhan, Mohit, et al.
Publicado: (2022)

The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity
por: Ho, Cyrus Su Hui, et al.
Publicado: (2023)

The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
por: Laramée, Philippe, et al.
Publicado: (2014)

Major Depression Impairs the Use of Reward Values for Decision-Making
por: Rupprechter, Samuel, et al.
Publicado: (2018)

Neurobiological and pharmacological arguments for customization of cognitive behavioral psychotherapy in the treatment of major depressive disorder
por: Ristea, Silvia, et al.
Publicado: (2021)

The effectiveness of electroconvulsive therapy in substance use disorder at pharmacological treatment failure major depression
por: Dannon, P.
Publicado: (2023)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl, Katharina, et al.
Publicado: (2014)

Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
por: Weiss, Catherine, et al.
Publicado: (2021)

Severe anorexia nervosa, co-occurring major depressive disorder and electroconvulsive therapy as maintenance treatment: a case report
por: Poutanen, Outi, et al.
Publicado: (2009)

TPH1 A218C polymorphism and temperament in major depression
por: Andre, Kadri, et al.
Publicado: (2013)

Multiple Facets of Value-Based Decision Making in Major Depressive Disorder
por: Mukherjee, Dahlia, et al.
Publicado: (2020)

The Utility of CYP2D6 and CYP2C19 Variants to Guide Pharmacological Treatment in Complex Unipolar Major Depression: A Pilot Longitudinal Study
por: Ramaraj, Reshma, et al.
Publicado: (2023)

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder
por: Sobocki, P, et al.
Publicado: (2008)

On the Use of Aggregate Survey Data for Estimating Regional Major Depressive Disorder Prevalence
por: Morales, Domingo, et al.
Publicado: (2021)

The pharmacological management of depression
por: Kupfer, David J.
Publicado: (2005)

Pharmacological and Non-pharmacological Treatment Options for Depression and Depressive Symptoms in Hemodialysis Patients
por: Grigoriou, Stefania S., et al.
Publicado: (2015)

Medicines, environment and clinical pharmacology
por: Lapatto‐Reiniluoto, Outi, et al.
Publicado: (2022)

Guidelines for the pharmacological acute treatment of major depression: conflicts with current evidence as demonstrated with the German S3-guidelines
por: Plöderl, Martin, et al.
Publicado: (2019)

Integrated network pharmacology and hepatic metabolomics to reveal the mechanism of Acanthopanax senticosus against major depressive disorder
por: Gu, Xinyi, et al.
Publicado: (2022)

Antidepressant effect r TMS during pregnancy in a case of Major Depression Resistant to Pharmacological Treatment
por: Isabel, Martínez-Gras, et al.
Publicado: (2021)

Assessment of outcome measures for cost–utility analysis in depression: mapping depression scales onto the EQ-5D-5L
por: Gamst-Klaussen, Thor, et al.
Publicado: (2018)

Impact of the COVID-19 Pandemic on Healthcare Resource Utilization in Individuals with Major Depressive Disorder
por: Liberman, Joshua N., et al.
Publicado: (2022)

The Pharmacology and Therapeutic Utility of Sodium Hydroselenide
por: Samra, Kavitej, et al.
Publicado: (2021)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uomrud3aor3321g077d4245f0e